anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for whitening teeth which utilizes laser light to activate bleaching agents applied to the teeth. The mouth is first prepared so that the soft tissues of the gums are protected and only the teeth are exposed. The teeth are cleaned to remove any materials which will reduce or nullify the effects of the bleaching agents. A first bleaching composition comprising a peroxide compound is prepared and applied to the teeth. The teeth are exposed to laser light from an argon laser which light activates the peroxide to accelerate the bleaching process without heat. If further whitening is desired, a second bleaching composition comprising a peroxide compound is prepared and applied to the teeth. The teeth are briefly exposed to laser light from a carbon dioxide laser which heat activates the peroxide to accelerate the bleaching process.
The primary outcome is the mortality rate 30 days after the ICU-based mechanical ventilation initiation.Based on current data available, the mortality rate for ventilated patients is assumed to be 80% in the current design. An interim futility analysis will be conducted after 16 evaluable patients have received the ultralow dose-whole lung radiation therapy (ULD-WLRT). If at least 3 patients survive for at least 30 days, we will enroll additional 8 patients (total of 24 patients). Otherwise, the trial will stop for further evaluation. Due to the limited data currently available in local institutions about a 30 day mortality rate , we will retrospectively evaluate the mortality rate of the ventilated patients without the ULD-WLRT in our institution when data is available.

Time to event secondary objectives (e.g. overall survival, time to discharge) analyses will be performed using Kaplan-Meier survival analysis, with a competing risk model (leaving the study because of death), including effects for demographic/clinical characteristics in the model. Proportional endpoints (such as % patients off ventilator) will be calculated along with the 95% Clopper-Pearson exact confidence interval. Pre/post measurements will be evaluated using linear mixed models for repeated measures (with proper data transformation as needed). Association between demographic/clinical characteristics and other secondary objectives (size of ground glass opacities (GGO)/opacification, for example) will be accomplished with generalized linear models.
Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146pos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.
Novel hetero-branched cyclodextrins each having a glucosyl or maltosyl group as the side chain, in which a mannosyl group is .alpha. -bonded to the hydroxyl group of the glucosyl group of the side chain; and a method of preparing the same.      In accordance with the present invention using the transglycosylation action of .alpha. -mannosyl transferases, novel hetero-branched CDs each having a glucosyl or maltosyl group as the side chain, in which a mannosyl group is .alpha. -bonded to the hydroxyl group of the glucosyl group of the side chain, may be obtained efficiently. The novel hetero-branched CDs of the present invention are expected to be utilized widely in various fields of drugs, foods and cosmetics.
FIELD: veterinary medicine. SUBSTANCE: colostrum product-based drug contains formaldehyde and physiological salt solution. The colostrum product is dry whey. The content of ingredients is as follows (% weight): dry colostrum whey 6-7, formaldehyde 0.08-0.12, physiological salt solution - the rest. The method involves intramuscular administration of doses of the said drug (2.5-3.5 ml) one time or two times daily until recovery. EFFECT: higher treatment efficacy. 2 cl, 1 tbl
The field of the invention generally relates to a shellac-based enteric coating with a reliable and consistent dissolution profile in both acid and neutral environments based on the selective choice of coating excipients used with the shellac. The enteric coating formulation includes a shellac, a maltrin, sodium alginate, one or more plasticizers, and optionally talc. The shellac is present in a range of approximately 40% to 60% w/w % and has an acid number of between 71 and 73. The maltrin is present in a range of approximately 15% to 30% w/w %. The sodium alginate is present in a range of approximately 15% to 30% w/w %. The one or more plasticizers are present in a range of approximately 2% to 20% w/w %. The optional talc is present in a range of 0% to 10%.
Co-administration of Tadalafil Tablets in Patients on Ritonavir

In patients receiving ritonavir for at least one week, start tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].

Co-administration of Ritonavir in Patients on Tadalafil Tablets

Avoid use of tadalafil tablets during the initiation of ritonavir. Stop tadalafil tablets at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume tadalafil tablets at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].
The department of surgery at Tian Jin Medical University Cancer Hospital, one of the centers of excellence to treat patients with breast cancer in China, collects and maintains an electronic database of patients treatment details and follow up data. This is a single centre, observational and retrospective clinical study. The study group was about all HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted AI therapy with the completed follow-up data.All the enrolled patients received breast-conserving surgery or whole breast surgery, and afterwards, received adjuvant chemotherapy according the pathological types. The patient's clinical pathological data include the age, family history, surgery options, pathologic type, the size of tumor, lymph node status, histological grade, chemotherapy regime, irradiation regime, and the expressions pattern of Her-2 and Ki-67. The research starts when the patients received the first time AI treatment. In the subsequent treatment, we analyzed the patients' bone density changes (T value \>-1 indicates normal,-2.5≤T value≤-1 indicates mild osteoporosis, T value \<-2.5 indicates severe osteoporosis) each half year for 3 years, analyzed the patients' liver function and kidney function changes each half year for 3 years (AST, ALT, ALP, TBIL, DBIL,UREA and CREA values \> 2 times ULN indicates abnormal), analyzed the patients' blood-lipoids (LDL, HDL, TG and TC) each half year for 3 years, the occurrence rates of adverse reactions (skin flush, joint pain, headache, rash, nausea, vomiting, diarrhea, et al), the causes and rates of treatment termination between the 2 groups, the 3 years DFS and OS between two groups, and the factors associated with survival and prognosis, and identified the benefit individuals of AI therapy.
BACKGROUND: Parkinson's Disease (PD) is a progressive neurological disorder that results in potentially debilitating mobility deficits. Recently, spinal cord stimulation (SCS) has been proposed as a novel therapy for PD gait disorders. The highest levels of evidence remain limited for SCS.
OBJECTIVES: In this systematic review and narrative synthesis, the literature was searched using combinations of key phrases indicating spinal cord stimulation and PD.
METHODS: We included pre-clinical studies and all published clinical trials, case reports, conference abstracts as well as protocols for ongoing clinical trials. Additionally, we included trials of SCS applied to atypical parkinsonism.
RESULTS: A total of 45 human studies and trials met the inclusion criteria. Based on the narrative synthesis, a number of knowledge gaps and future avenues of potential research were identified. This review demonstrated that evidence for SCS is currently not sufficient to recommend it as an evidence-based therapy for PD related gait disorders. There remain challenges and significant barriers to widespread implementation, including issues regarding patient selection, effective outcome selection, stimulation location and mode, and in programming parameter optimization. Results of early randomized controlled trials are currently pending. SCS is prone to placebo, lessebo and nocebo as well as blinding effects which may impact interpretation of outcomes, particularly when studies are underpowered.
CONCLUSION: Therapies such as SCS may build on current evidence and be shown to improve specific gait features in PD. Early negative trials should be interpreted with caution, as more evidence will be required to develop effective methodologies in order to drive clinical outcomes.
In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m\^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
The invention discloses a bivalent inactivated vaccine for mycoplasma ovis pneumonia and chlamydia psittaci disease and a preparation method thereof. The active ingredients of the bivalent inactivated vaccine comprise MOMP proteins of inactivated mycoplasma ovipneumoniae and inactivated chlamydia psittaci. The amino acid sequence of the MOMP protein of Chlamydia psittaci is shown as sequence 2 in the sequence table. The Mycoplasma ovipneumoniae is Mycoplasma ovipneumoniae (Mycoplasma ovipneumaniae) SH-01CGMCC No. 16503. Experiments prove that the bivalent inactivated vaccine has good safety for immunizing experimental animals (such as guinea pigs, rabbits and Beagle dogs) and target animals (such as sheep), and can effectively prevent the experimental animals and the target animals from being infected by the mycoplasma pneumoniae of the sheep and the chlamydia psittaci. Has important practical significance for preventing and controlling the prevalence and the spread of the mycoplasma pneumoniae of sheep and the chlamydia psittaci disease. The invention has important application value.
The pharmacist prepares milrinone 20 mg with normal saline solution (NSS) 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours. The doctor performs Echocardiogram before start Milrinone, during infusion, and after 12 hours from stop Milrinone. Other medications or interventions were used or not used depending on own doctor.
A focus detection apparatus and a method thereof are provided. In the method, a medical image at a first location is obtained, and a first focus is identified on the medical image of the first location. Another medical image at a second location is obtained, and a second focus is identified on the medical image of the second location. Then, whether the second focus is the first focus is determined. If the second focus is the first focus, the first and second focus is combined as a single focus to be presented. Accordingly, every medical image can be determined whether is the same focus as the previously identified focus in order, so as to provide more complete information for instant aided detection technology.
In this group, the number of flashes per row and column during the P300 speller training will be chosen randomly. It is independent of the participants' performance.
Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers \[8\]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
Elderly

For elderly patients treated with Risperidone for Extended-Release Injectable Suspension, the recommended dosage is 25 mg intramuscular every 2 weeks. Oral risperidone (or another antipsychotic medication) should be given with the first injection of Risperidone for Extended-Release Injectable Suspension and should be continued for 3 weeks to ensure that adequate therapeutic plasma concentrations are maintained prior to the main release phase of risperidone from the injection site [see Clinical Pharmacology (12.3)].

Renal or Hepatic Impairment

Patients with renal or hepatic impairment should be treated with titrated doses of oral risperidone prior to initiating treatment with Risperidone for Extended-Release Injectable Suspension. The recommended starting dose is 0.5 mg oral risperidone twice daily during the first week, which can be increased to 1 mg twice daily or 2 mg once daily during the second week. If a total daily dose of at least 2 mg oral risperidone is well tolerated, an injection of 25 mg Risperidone for Extended-Release Injectable Suspension can be administered every 2 weeks. Oral supplementation should be continued for 3 weeks after the first injection until the main release of risperidone from the injection site has begun. In some patients, slower titration may be medically appropriate. Alternatively, a starting dose of Risperidone for Extended-Release Injectable Suspension of 12.5 mg may be appropriate. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.

Patients with renal impairment may have less ability to eliminate risperidone than normal adults. Patients with impaired hepatic function may have an increase in the free fraction of the risperidone, possibly resulting in an enhanced effect [see Clinical Pharmacology (12.3)]. Elderly patients and patients with a predisposition to hypotensive reactions or for whom such reactions would pose a particular risk should be instructed in nonpharmacologic interventions that help to reduce the occurrence of orthostatic hypotension (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position). These patients should avoid sodium depletion or dehydration, and circumstances that accentuate hypotension (alcohol intake, high ambient temperature, etc.). Monitoring of orthostatic vital signs should be considered [see Warnings and Precautions (5.7)].
In Japan and in some western treatment centers, there has been a general belief that more extensive surgery may improve outcome for patients with localized, operable pancreatic adenocarcinoma. Initial retrospective reports from centers in Japan suggested that 5-year overall survival rates in patients treated with pancreaticoduodenectomy plus extended lymphadenectomy were higher than those in patients treated by pancreaticoduodenectomy with standard lymphadenectomy. Subsequent prospective randomized trials performed in Europe and the United States failed to confirm a survival benefit from extended lymphadenectomy. Although they failed to confirm a survival benefit from extended lymphadenectomy, the studies had a few pitfalls. The need for Well-designed randomised controlled study is the starting point of our study. This study was designed to test the hypothesis that more extensive nodal and soft-tissue clearance in patients with adenocarcinoma of the head of the pancreas would improve survival without an increase in morbidity and mortality.
Functional dyspepsia (FD) is a functional gastrointestinal disorder without any structural lesion. Due to the lack of satisfactory effect of conventional treatments, many FD patients turn to alternative treatments such as acupuncture. Acupuncture, one of the most sought therapeutic modalities in traditional Korean Medicine, has been commonly used for treating gastrointestinal disorders.

However, the effect and mechanism of acupuncture on FD has not been rigorously evaluated. In the present study, we will investigate whether 10 sessions of acupuncture over 4 weeks, in comparison with sham acupuncture, improve symptoms of FD and activate regions of brain area. We will also perform metabolomics study to find the mechanism of acupuncture to FD. Outcome measures include proportion of responder, Korean version of Nepean Dyspepsia Index, Functional Dyspepsia-Related Quality of Life, Ways of Coping Question, Coping Strategy Questionnaire, Perception of bodily sensation, The State-Trait Anxiety Inventory, Center for Epidemiologic Studies Depression Scale, functional magnetic resonance imaging and metabolomic study.
A device and method for umbilicus protection during abdominal surgery; and, especially plastic reconstructive and aesthetic surgery requiring umbilicoplasty and/or umbilicus transposition is provided. The device embodies an umbilicus shield, which envelops the umbilical pedicle during abdominal surgery. The device can include a tubular element, having a distal end and a proximal end, containing near its proximal end, means for releasabley retaining suture material from tacking stitches taken in the umbilicus to provide means for drawing the umbilical pedicle into the tubular element. The suture material is advantageously drawn through the tubular element by means of a suture shuttle which contains, proximate its distal end, means for releasabley retaining the suture material. The device facilitates umbilicoplasty and umbilicus transposition during abdominal surgery; prevents nicks or cuts during circum umbilicus dissection; prevents nicks, cuts, or amputation of the umbilicus during defattening; and, reduces the possibility of umbilical pedicle strangulation during rectus abdominis musculoaponeurotic plication. The method prevents such strangulation and assures proper positioning of the orifice and umbilicus during umbilicus transpositions.
An analysis and visualization system analyzes a digital image of a tissue sample. In the sample, cells of a first type are stained in a first way, and cells of a second type are stained in a second way. The system segments the high-resolution image into first and second objects representing cells of the first and second types, respectively. The system also identifies a region of interest, and divides it into tiles. The system generates, for each tile, a first value and a second value. The first and second values for a tile are indicative of densities of the first and second objects in the tile. From the values, a measured correlation coefficient (CC) value is determined. The system compares the measured CC value to a reference CC value, thereby obtaining a correspondence value. The system then displays the image region along with a visualization of the correspondence value.
ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
BACKGROUND: Colonic fibrosis has important clinical implications in ulcerative colitis [UC]. Ultrasound imaging has emerged as a convenient and reliable tool in diagnosis of inflammatory bowel disease. We aimed to explore the potential use of ultrasound to evaluate UC fibrosis.
METHODS: Consecutive UC patients who had proctocolectomy from July 2022 to September 2023 were enrolled in the study. Patients underwent bowel ultrasound examination and ultrasound elastography imaging prior to surgery. Milan ultrasound criteria [MUC] were calculated and bowel wall stiffness was determined using two mean strain ratios [MSRs]. Degree of colonic fibrosis and inflammation was measured upon histological analysis. Receiver operating characteristic [ROC] analysis was used to evaluate the performance of ultrasound-derived parameters to predict fibrosis.
RESULTS: In all, 56 patients were enrolled with 112 segments included in analysis. The median fibrosis score was 2 [0-4] and the median Geboes score was 5 [0-13] and these two scores were significantly correlated [p < 0.001]. The muscularis mucosa thickness was significantly higher in moderate-severe fibrosis than none-mild fibrosis [p = 0.003] but bowel wall thickness was not [p = 0.082]. The strain ratios [p < 0.001] and MUC [p = 0.010] were significantly higher in involved than non-involved segments. The strain ratios were correlated with fibrosis score [p < 0.001] but not MUC [p = 0.387]. At ROC analysis, mean strain ratio 1 [MSR1] had an area under the curve [AUC] of 0.828 [cutoff value 3.07, 95% CI 0.746-0.893, p < 0.001] to predict moderate-severe fibrosis.
CONCLUSION: Ultrasound elastography imaging could predict the degree of colonic fibrosis in UC. Application of this technique could help disease monitoring and decision making in UC patients.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be applied for treatment of duodenum ulcerous disease in children (UDD). For this purpose in complex therapy included is fluconazole (diflucan). Doses and regime of fluconazole introduction are determined depending on the level of circulating candidal antigen in blood serum. At high level of candidal antigenemia (10-4/10-5 mg/ml) medication is administered in form of intravenous injections in dose 5 mg/kg 1 time per day during 3 days, then 7 days inside in dose 3 mg/kg, and after that 1 time per week once during a month in dose 150 mg. At moderate level of candidal antigenemia (10-6 /10-7 mg/ml) flucanazole is administered inside by 5 mg/kg during 7 days, then 1 time per week in dose 150 mg during a month. At low level of candidal antigen in blood serum (10-8 /10-9 mg/ml) medication is taken inside in dose of 3 mg/kg during 7 days, then once in dose 150 mg. ^ EFFECT: method makes it possible to reduce level of circulating candidal antigen in blood serum of patients with any level of candidal antigenemia. ^ 3 ex
Vascular calcification, a major risk factor for cardiovascular events, is associated with a poor prognosis in chronic kidney disease (CKD) patients. This process is often associated with the transformation of vascular smooth muscle cells (VSMCs) into cells with osteoblast-like characteristics. Damage-associated molecular patterns (DAMPs), such as extracellular histones released from damaged or dying cells, are suspected to accumulate at calcification sites. To investigate the potential involvement of DAMPs in vascular calcification, we assessed the impact of externally added histones (extracellular histones) on calcium and inorganic phosphate-induced calcification in mouse VSMCs. Our study found that extracellular histones intensified calcification. We also observed that the histones decreased the expression of VSMC marker genes while simultaneously increasing the expression of osteoblast marker genes. Additionally, histones treated with DNase I, which degrades dsDNA, attenuated this calcification, compared with the non-treated histones, suggesting a potential involvement of dsDNA in this process. Elevated levels of dsDNA were also detected in the serum of CKD model mice, underlining its potential role in vascular calcification in CKD. Our findings suggest that extracellular histones could play a pivotal role in the vascular calcification observed in CKD.
Participants undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes.